Tang Lichun, Zeng Yanting, Du Hongzi, Gong Mengmeng, Peng Jin, Zhang Buxi, Lei Ming, Zhao Fang, Wang Weihua, Li Xiaowei, Liu Jianqiao
State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, 27 Taiping Road, Beijing, 100850, China.
National Center for Protein Sciences Beijing, Life Sciences Park, Beijing, 102206, China.
Mol Genet Genomics. 2017 Jun;292(3):525-533. doi: 10.1007/s00438-017-1299-z. Epub 2017 Mar 1.
Previous works using human tripronuclear zygotes suggested that the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system could be a tool in correcting disease-causing mutations. However, whether this system was applicable in normal human (dual pronuclear, 2PN) zygotes was unclear. Here we demonstrate that CRISPR/Cas9 is also effective as a gene-editing tool in human 2PN zygotes. By injection of Cas9 protein complexed with the appropriate sgRNAs and homology donors into one-cell human embryos, we demonstrated efficient homologous recombination-mediated correction of point mutations in HBB and G6PD. However, our results also reveal limitations of this correction procedure and highlight the need for further research.
以往利用人类三原核受精卵开展的研究表明,成簇规律间隔短回文重复序列(CRISPR)/Cas9系统可能是一种纠正致病突变的工具。然而,该系统是否适用于正常人类(双原核,2PN)受精卵尚不清楚。在此,我们证明CRISPR/Cas9作为一种基因编辑工具在人类2PN受精卵中同样有效。通过将与合适的单向导RNA和同源供体复合的Cas9蛋白注射到单细胞人类胚胎中,我们证明了能通过高效的同源重组介导纠正HBB和G6PD中的点突变。然而,我们的结果也揭示了这种纠正程序的局限性,并突出了进一步研究的必要性。